Arietta.ai

I'm incredibly honored and excited to share that Arietta AI's LucidPV has been featured in USA Today! The article highlights how LucidPV is revolutionizing pharmacovigilance with advanced AI technology. By leveraging cutting-edge AI, we're enhancing drug safety and monitoring, ensuring better patient outcomes and more efficient regulatory compliance. Our innovative solution addresses the critical need for robust and proactive pharmacovigilance in today's fast-paced medical landscape. A huge thank you to USA Today for spotlighting our efforts and the impact of LucidPV in the field of pharmacovigilance. This recognition inspires us to continue pushing the boundaries of what's possible with AI in healthcare. Check out the full article:  https://lnkd.in/ezSbigxp. #AriettaAI #LucidPV #Pharmacovigilance #USAToday #AIinHealthcare #Innovation #DrugSafety #Gratitude #AI #HealthcareInnovation

Attending DIA 2024 in San Diego starting this Sunday evening June 16-20? Arietta.ai will be exhibiting and giving demos of LucidPV, our industry leading product delivering advanced AI and automation to patient safety teams. We would love to see you and talk about how LucidPV and and the use of AI can help you and your teams achieve new levels of speed and quality.

Responsible AI – The Application of Advanced AI in Pharmacovigilance Arietta.ai, a leader in life sciences Applied AI solutions, is presenting at the Pharmacovigilance Europe 2024: The 11th Annual International Conference And Exhibition In Pharmacovigilance, Regulatory Affairs, Risk Management And Clinical Trials in London, UK on May 15, 2024. Tim Howard, CEO of Arietta.ai, will discuss responsible application in pharmacovigilance. His presentation will explore the multiple dimensions of responsibility that must be considered for successful AI adoption by drug safety teams. “Patient, pharmacovigilance staff, and regulator perspectives must be integrated into an expanded definition of what Responsible AI adoption means when it comes to drug safety. An inclusive approach sets the foundation for near and long term success and acceptance of applied Ai solutions,” commented Tim Howard. "Superior large language model based extraction and classification must be coupled with a robust security architecture providing full transparency and accountability." The presentation and discussion will address the importance of considering patient privacy, the impact on staff responsibilities, regulatory requirements, and how they must be inherent in AI solutions. Tim will join other leaders in pharmacovigilance and technology to discuss the ongoing challenges in drug safety data management, analysis, signal detection, and reporting. For further inquiries or to schedule a meeting, contact us here: https://lnkd.in/gUtBQish. Additional information about the conference including registration can be found at https://pveurope.com/.

LucidPV v24.0 Release Achieves General Availability LucidPV, the industry’s most advanced LLM-based AI product for Pharmacovigilance intake and triage, today achieved general availability of v24.0. The new version of LucidPV adds significant advancements that solve for more challenges that safety teams face with an increasingly complex range of sources, formats, content, and seriousness levels of adverse event reports. In response to customer feedback, LucidPV v24.0 adds 113 key enhancements and features including capabilities such as: automated translation of adverse event reports from more than 70 languages, AI-powered automated Initial/Follow-up/Duplicate classification, and Literature Abstract extraction and classification. Customer benefits of LucidPV include: --- ROI amplification: Increases the impact, speed, and effectiveness of current teams, systems, and workflows --- Seamless automation: Accelerates case receipt, triage, and book-in without disruption to current PV processes --- Reliably fast implementation: Can be up and running in a matter of weeks, not months or years --- Full control and visibility: Better transparency and measurability of all PV performance, trends, and bottlenecks --- Continuous learning: Incorporates user feedback, new data, and new technology to learn and improve over time “This kind of rapid advancement is what PV teams need to keep pace with demands. The latest version of LucidPV delivers a fast ROI by saving customers time and improving quality within their patient safety operations,” said Nick Hermann, Arietta’s Chief Customer Officer. “Having supported many customers through implementations, I’m excited how LucidPV can be stood up quickly with out-of-the-box pre-trained AI.” “We continue to take an AI-first approach to designing and developing LucidPV v24.0. This enables us to build responsible AI solutions that are elegant, fast and easy for customers to integrate into their existing workflow and systems,” said Mike Weber, Arietta’s Chief Product Officer.  LucidPV v24.0 is available now to organizations who are looking to leverage AI and large language models to automate their patient safety processes without impacting their current investments in existing technology. Trial versions are also available. To request more information please contact Arietta.ai here: https://lnkd.in/gUtBQish

Adopting AI-Driven Automation in Pharmacovigilance AND Achieving a Compelling ROI ------------------------- Arietta.ai, a leader in life science Applied AI solutions, is slated to present at the 35th Pharmacovigilance 2024 Conference in Boston, MA on May 3, 2024. Tim Howard, CEO of Arietta.ai, will delve into the pivotal role accelerated ROI plays in achieving a successful initial rollout of advanced AI by pharmacovigilance departments. "Adapting to executives' expectations regarding AI adoption is pivotal for strategic alignment within organizations. By approaching Applied AI integration in drug safety with a focused lens, we can achieve significant process enhancements while realizing a significant ROI within 12 months," commented Tim Howard. PV leaders are best served by de-emphasizing the transformative potential of Advanced AI and focusing on the pragmatic benefits of realized time and cost savings and building trust in the underlying AI models.  Quick wins that reinforce AI’s role to assist, and not replace, medical experts establish a foundation for long term success and innovation. "The adoption of LucidPV as an Applied AI point solution for pharmacovigilance supports organizational objectives and provides tangible evidence of the profound impact focused AI solutions can have on overall business success," remarked James Brooks, Chairman of Arietta.ai. Tim joins other pharmacovigilance and technology leaders to discuss prevalent challenges in drug safety data collection, analysis, signal detection, and reporting. The event provides a valuable platform for networking, knowledge exchange, and professional development. Tim's presentation is scheduled for Friday, May 3rd, at 9:40 am, followed by a Q&A session and networking opportunities. For further inquiries or to schedule a meeting, contact us here: https://lnkd.in/gUtBQish. Additional details about the conference are available at https://lnkd.in/eypUV5y7.

Adopting AI-Driven Automation in Pharmacovigilance AND Achieving a Compelling ROI ------------------------- Arietta.ai, a leader in life science Applied AI solutions, is slated to present at the 35th Pharmacovigilance 2024 Conference in Boston, MA on May 3, 2024. Tim Howard, CEO of Arietta.ai, will delve into the pivotal role accelerated ROI plays in achieving a successful initial rollout of advanced AI by pharmacovigilance departments. "Adapting to executives' expectations regarding AI adoption is pivotal for strategic alignment within organizations. By approaching Applied AI integration in drug safety with a focused lens, we can achieve significant process enhancements while realizing a significant ROI within 12 months," commented Tim Howard. PV leaders are best served by de-emphasizing the transformative potential of Advanced AI and focusing on the pragmatic benefits of realized time and cost savings and building trust in the underlying AI models.  Quick wins that reinforce AI’s role to assist, and not replace, medical experts establish a foundation for long term success and innovation. "The adoption of LucidPV as an Applied AI point solution for pharmacovigilance supports organizational objectives and provides tangible evidence of the profound impact focused AI solutions can have on overall business success," remarked James Brooks, Chairman of Arietta.ai. Tim joins other pharmacovigilance and technology leaders to discuss prevalent challenges in drug safety data collection, analysis, signal detection, and reporting. The event provides a valuable platform for networking, knowledge exchange, and professional development. Tim's presentation is scheduled for Friday, May 3rd, at 9:40 am, followed by a Q&A session and networking opportunities. For further inquiries or to schedule a meeting, contact us here: https://lnkd.in/gUtBQish. Additional details about the conference are available at https://lnkd.in/eypUV5y7.

Questions about reliability, cost, or regulatory compliance with AI in pharmacovigilance and patient safety? Learn about fresh and practical ideas for adopting advanced AI in PV with our executive briefing at the following link: https://lnkd.in/gVzQM7Tm #AI #ArtificialIntelligence #Pharmacovigilance

Arietta.ai will be showcasing our LLM-based automate extraction and classification Life Science solutions at J.P. Morgan in January.